Rafael Bejar
YOU?
Author Swipe
View article: Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study
Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study Open
Introduction Defining the epidemiology of myelodysplastic syndromes/neoplasms (MDS) and precursor conditions, such as clonal cytopenia of undetermined significance (CCUS), is challenging due to inconsistent reporting, complex diagnostics, …
View article: Error-corrected sequencing to quantify clonal hematopoiesis in breast cancer survivors treated with metformin in a randomized, placebo controlled, prospective clinical trial
Error-corrected sequencing to quantify clonal hematopoiesis in breast cancer survivors treated with metformin in a randomized, placebo controlled, prospective clinical trial Open
BACKGROUND: Targeting clonal hematopoiesis (CH) in an interventional clinical study involves significant challenges including: a lack of validated endpoints, long follow-up time, uncertainty about baseline risk, intolerance for drug-relate…
View article: Broadening the differential diagnosis associated with germline DDX41 mutations
Broadening the differential diagnosis associated with germline DDX41 mutations Open
Not available.
View article: Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 5
View article: Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Information on antibody RRID and Other catalog numbers
View article: Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 6
View article: Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 3
View article: Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 7
View article: Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Table file to be published with manuscript
View article: Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 8
View article: Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 4
View article: Suppl Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 2
View article: Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 1
View article: Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 8 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 8
View article: Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 3 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 3
View article: Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 4
View article: Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Information on antibody RRID and Other catalog numbers
View article: Suppl Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 2 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 2
View article: Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 6 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 6
View article: Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 1
View article: Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 7 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 7
View article: Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 5 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 5
View article: Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Supplementary Tables from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Table file to be published with manuscript
View article: Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacitidine
Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacitidine Open
Myelodysplastic syndromes (MDS) are characterized by aberrant DNA methylation, and mutations in epigenetic modifiers are frequently found in these patients. Although DNA methyltransferase inhibitors (DNMTi) are used to treat MDS, response …
View article: Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement Open
Excessively restrictive inclusion and exclusion criteria in clinical trials are one of many barriers to clinical trial enrollment for patients with myelodysplastic syndromes/neoplasms (MDSs). Many organizations are developing efforts to in…
View article: Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 1 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 1
View article: Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Supplementary Data from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Information on antibody RRID and Other catalog numbers
View article: Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia
Suppl Figure 4 from Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia Open
Supplementary Figure 4